<DOC>
	<DOCNO>NCT02565992</DOCNO>
	<brief_summary>This study employ phase Ib design use establish dose CAVATAK pembrolizumab subject advance melanoma pembrolizumab would consider standard care . Our hypothesis oncolysis melanoma cell CAVATAK important amplify T-cell potentiating effect pembrolizumab .</brief_summary>
	<brief_title>Phase I Study Intratumoral CAVATAKâ„¢ Pembrolizumab Subjects With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Subjects metastatic unresectable stage IIIb/c IV melanoma treatment pembrolizumab indicate least one cutaneous , subcutaneous tumor palpable lymph node amenable intratumoral injection . At least one tumor must qualify index lesion modify WHO criteria . Subjects must adequate hematologic , hepatic renal function . ECOG performance status 0 1 . Anticipated lifespan great 12 week Mucosal ocular primary tumor . Presence central nervous system tumor stable least 4 week corticosteroid . Tumors lie mucosal region close airway , major blood vessel spinal cord . Subjects active , know suspect autoimmune immunosuppressive disease . Subjects previously treat CVA21 antiPD1/ PDL1 agent . Subjects require systemic treatment corticosteroid immunosuppressive medication within 14 day prior first treatment . Subject receive chemotherapy within last 4 week prior first treatment . Clinically significant cardiovascular disease . Females childbearing potential must negative serum urine pregnancy test . Subjects require use investigational agent treatment trial . History malignancy within last 3 year ( exception ) . Active infection require systemic therapy . Known history HIV disease , active hepatitis B hepatitis C. History evidence clinically significant disorder would pose risk subject safety . Inability give inform consent comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pembrolizumab</keyword>
	<keyword>coxsackievirus A21</keyword>
</DOC>